// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Evolving patterns of reactive arthritis

K.M. Hayes - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Exceeding predefined thresholds for mri bone oedema and erosion and haq-di can predict relapse after withdrawal of all treatment in mtx-naÏve patients with ra in remission after 12 months of abatacept therapy in the avert trial

H.A. Ahmad - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Abatacept

Experience with subcutaneous abatacept in routine clinical practice: 6-month interim analysis of a 2-year, prospective, non-interventional, multicentre study in patients with ra

R. Alten - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Abatacept

Exploration of t-cell signatures following tcr stimulation using single cell rna-seq to inform treatment response studies in rheumatoid arthritis

P. Martin - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Exploring pain and the impact of jia on adolescents and young adults: a mixed-methods study

H Chaplin - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Facilitating patient centred care: the development of illustrated multidimensional patient reported outcome measure for children with juvenile idiopathic arthritis

Y. El Miedany - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Factors associated with the development of esrd in a recent large single centre cohort of patients with lupus nephritis

I. Dasilva Santos - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus nephritis

Rituximab

Factors determining work instability in patients with axial spondyloarthritis

A.S. Buche - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Fast access to assessment support and treatment (FAAST: innovation to improve service

R. Laxminarayan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood

A. Tincani - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Febuxostat versus allopurinol streamlined trial (FAST: baseline characteristics of the randomised patient population

I. Mackenzie - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Myocardial infarction

Allopurinol

Fibroblast-matrix-vessel: the unhappy triad

C.P. Denton - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Fibromyalgia onset of systemic lupus erythematosus?

N. Hassan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Finger flexor tendon pulley complex involvement in psa dactylitis: an ultrasonography study

I. Tinazzi - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Dactylitis

Orphenadrine Citrate

First diagnosis of uveitis is not higher among juvenile idiopathic arthritis (JIA patients receiving etanercept compared to methotrexate

R. Davies - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

First validation of consensus definitions for mri lesions in the sacroiliac joint by the assessments in spondyloarthritis international society (ASAS mri group

W.P. Maksymowych - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

Five-year progression of rheumatoid arthritis disease activity and quality of life in 2002 and 2011. have reductions in disease activity in recent years resulted in improvements in quality of life?

L. Carpenter - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Foetal-neonatal and maternal outcomes in women with rheumatoid arthritis

Y.-C. Tsai - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Functional characterization of the sjögren’s syndrome-associated locus ddx6-cxcr5

S. Khanam - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

Functional rehabilitation for the relief of complex persistent pain

C. Mccabe - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Complex regional pain syndrome

N/A

Copyright © 2026. QuantiNova All rights reserved